



January 27, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Executive Corporate Officer and General Manager, Corporate Strategy (TEL: 81-3-6838-2803)

Conclusion of Capital and Business Alliance with Surv BioPharma Inc.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro, hereinafter “TOHO HOLDINGS”) announces that it has agreed to enter into a capital and business alliance with Surv BioPharma Inc. (Headquarters: Kagoshima; President and CEO: Masaki Yamada; hereinafter “Surv BioPharma”), as described below.

1. Reason for capital and business alliance

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Surv BioPharma is a certified bio-venture company originating from Kagoshima University, established in August 2022. The company is currently engaged in research and development toward the social implementation of the oncolytic virus “Surv.m-CRA (Survivin-responsive, multi-factorially regulated conditionally replicating adenovirus)” series which was originally developed by Dr. Ken-ichiro Kosai, Professor at Kagoshima University, who also serves as the Founder, Chairman, and Chief Scientific Officer (CSO) of Surv BioPharma. Surv.m-CRA-1 is Surv BioPharma’s proprietary oncolytic virus that incorporates “survivin promoter,” which is specifically activated in cancer cells. It replicates only in cancer cells and selectively destroys them without damaging normal cells, offering both high therapeutic efficacy and safety. Furthermore, it is expected to be a groundbreaking cancer therapy classified as a “regenerative medical product”, featuring the innovative ability to target cancer stem cells that are resistant to conventional therapies.

TOHO HOLDINGS has set Specialty Product Full-line Service as one of the specific measures of its Medium-term Management Plan, “Creating the Next Generation,” and is working to establish an essential positioning in domestic pharmaceutical distribution through the handling of specialty products, including regenerative medical products and other products for which future growth is expected. We have decided to invest in Surv BioPharma based on the judgment that the combination of Surv BioPharma’s research and development functions with the management resources of the Group will enable us to further strengthen our sales capabilities, acquire new expertise, and enhance our corporate value. In addition to supporting Surv BioPharma’s development through this investment, we will fully cooperate with Surv BioPharma in clinical trial logistics of its products. The Group will strive to deepen our knowledge of regenerative medical products and establish a stable distribution network to ensure that patients suffering from intractable diseases can receive innovative treatments with peace of mind.

2. Overview of Surv BioPharma

- | | |
|-----------------------|---|
| (1) Company name: | Surv BioPharma Inc. |
| (2) Location: | Graduate School of Medical & Dental Sciences, Kagoshima University
8-35-1, Sakuragaoka, Kagoshima-shi, Kagoshima, 890-8544 Japan |
| (3) Representative: | Masaki Yamada, President and CEO |
| (4) Established: | August 22, 2022 |
| (5) Business content: | Development & marketing of pharmaceutical products |
| (6) Capital: | JPY1,200,500,000 (including capital reserve) |

3. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to increase the Group's corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.

<p>Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.</p>
--